Malte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.

Neuronal hypersensitivity specialist NeRRe Therapeutics has closed an oversubscribed Series B financing round led by Fountain Healthcare Partners.

Novozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery. 

Milan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.

The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.

The London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.

French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheim’s consumer healthcare (CHC) business in exchange for Sanofi’s animal health arm Merial.

Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will take over as CEO of Viiv Healthcare. She succeeds Dominique Limet, who will step down from the post at the end of March 2017. 

Which European Biotechnology news stories topped the charts this year? The European Biotechnology team delved into archives and analysed the click statistics. And here they are: the most wanted news stories of 2016!

Co-founder of immuno-oncology start-up Innate Pharma Hervé Brailly is making room on the chair of the executive board. His successor Mondher Majhoubi transfers from AstraZeneca, where he was Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy.